Apollomics (APLM) Competitors $9.75 +0.38 (+4.06%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends APLM vs. TPST, AFMD, ANEB, FGEN, VRCA, IXHL, IRD, MDCX, RAPT, and OKURShould you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include Tempest Therapeutics (TPST), Affimed (AFMD), Anebulo Pharmaceuticals (ANEB), FibroGen (FGEN), Verrica Pharmaceuticals (VRCA), Incannex Healthcare (IXHL), Opus Genetics (IRD), Medicus Pharma (MDCX), RAPT Therapeutics (RAPT), and OnKure Therapeutics (OKUR). These companies are all part of the "pharmaceutical preparations" industry. Apollomics vs. Tempest Therapeutics Affimed Anebulo Pharmaceuticals FibroGen Verrica Pharmaceuticals Incannex Healthcare Opus Genetics Medicus Pharma RAPT Therapeutics OnKure Therapeutics Apollomics (NASDAQ:APLM) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking. Which has more volatility and risk, APLM or TPST? Apollomics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -1.78, indicating that its stock price is 278% less volatile than the S&P 500. Is APLM or TPST more profitable? Apollomics' return on equity of 0.00% beat Tempest Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ApollomicsN/A N/A N/A Tempest Therapeutics N/A -187.44%-82.61% Does the MarketBeat Community prefer APLM or TPST? Tempest Therapeutics received 96 more outperform votes than Apollomics when rated by MarketBeat users. However, 80.00% of users gave Apollomics an outperform vote while only 65.79% of users gave Tempest Therapeutics an outperform vote. CompanyUnderperformOutperformApollomicsOutperform Votes480.00% Underperform Votes120.00% Tempest TherapeuticsOutperform Votes10065.79% Underperform Votes5234.21% Do analysts prefer APLM or TPST? Apollomics currently has a consensus price target of $200.00, indicating a potential upside of 1,951.28%. Tempest Therapeutics has a consensus price target of $20.00, indicating a potential upside of 2,710.57%. Given Tempest Therapeutics' higher probable upside, analysts clearly believe Tempest Therapeutics is more favorable than Apollomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Tempest Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to APLM or TPST? In the previous week, Apollomics had 3 more articles in the media than Tempest Therapeutics. MarketBeat recorded 4 mentions for Apollomics and 1 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 0.38 beat Apollomics' score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apollomics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tempest Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, APLM or TPST? Tempest Therapeutics has lower revenue, but higher earnings than Apollomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApollomics$1.22M8.69-$172.60MN/AN/ATempest TherapeuticsN/AN/A-$29.49M-$1.53-0.47 Do insiders and institutionals hold more shares of APLM or TPST? 19.1% of Apollomics shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 4.7% of Tempest Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryTempest Therapeutics beats Apollomics on 7 of the 13 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLM vs. The Competition Export to ExcelMetricApollomicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.60M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E RatioN/A10.5991.3417.19Price / Sales8.69195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book0.215.104.794.78Net Income-$172.60M$151.51M$120.07M$225.60M7 Day Performance16.90%-2.15%-1.89%-1.24%1 Month Performance-3.47%-3.14%11.45%3.36%1 Year Performance-87.81%11.50%30.61%16.58% Apollomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLMApollomics1.4021 of 5 stars$9.75+4.1%$200.00+1,951.3%-87.3%$10.60M$1.22M0.0045News CoverageGap DownHigh Trading VolumeTPSTTempest Therapeutics1.8345 of 5 stars$0.81+1.0%$20.00+2,375.2%-80.7%$35.26MN/A-0.5320AFMDAffimed4.4532 of 5 stars$2.13-0.9%$13.50+533.8%-68.5%$34.29M$8.95M0.0076Analyst RevisionNews CoverageANEBAnebulo Pharmaceuticals1.9457 of 5 stars$1.30-7.1%$8.00+515.4%-52.9%$33.71MN/A-4.674News CoverageGap UpHigh Trading VolumeFGENFibroGen2.447 of 5 stars$0.33-2.3%N/A-29.9%$32.79M$180.02M-0.28486Analyst UpgradeAnalyst RevisionNews CoverageVRCAVerrica Pharmaceuticals4.6573 of 5 stars$0.71-6.4%$9.50+1,234.1%-87.7%$32.47M$5.12M-0.4040Analyst ForecastNews CoverageIXHLIncannex HealthcareN/A$1.83-1.6%N/A-54.1%$32.29M$86,000.00-1.343IRDOpus Genetics2.5364 of 5 stars$1.02flat$8.00+684.3%N/A$32.20M$8.38M-0.92N/ANews CoverageGap UpMDCXMedicus PharmaN/A$2.95+7.3%N/AN/A$32.00MN/A0.00N/AAnalyst ForecastRAPTRAPT Therapeutics4.5178 of 5 stars$0.91-0.3%$9.50+946.9%-96.1%$31.72M$1.53M-0.3380OKUROnKure Therapeutics3.4449 of 5 stars$9.25-6.2%$36.00+289.2%N/A$30.90MN/A-0.81N/AHigh Trading Volume Related Companies and Tools Related Companies Tempest Therapeutics Competitors Affimed Competitors Anebulo Pharmaceuticals Competitors FibroGen Competitors Verrica Pharmaceuticals Competitors Incannex Healthcare Competitors Opus Genetics Competitors Medicus Pharma Competitors RAPT Therapeutics Competitors OnKure Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APLM) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APLM Stock Alerts